- Home
- GOVX vs NERV Comparison
GOVX vs NERV Comparison
Compare GOVX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- NERV
- Stock Information
- Founded
- GOVX 2001
- NERV 2007
- Country
- GOVX United States
- NERV United States
- Employees
- GOVX N/A
- NERV N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- NERV Health Care
- Exchange
- GOVX Nasdaq
- NERV Nasdaq
- Market Cap
- GOVX 16.8M
- NERV 14.6M
- IPO Year
- GOVX N/A
- NERV 2014
- Fundamental
- Price
- GOVX $0.41
- NERV $3.78
- Analyst Decision
- GOVX Strong Buy
- NERV Hold
- Analyst Count
- GOVX 2
- NERV 1
- Target Price
- GOVX $7.00
- NERV $4.00
- AVG Volume (30 Days)
- GOVX 524.6K
- NERV 101.0K
- Earning Date
- GOVX 11-13-2025
- NERV 11-05-2025
- Dividend Yield
- GOVX N/A
- NERV N/A
- EPS Growth
- GOVX N/A
- NERV N/A
- EPS
- GOVX N/A
- NERV N/A
- Revenue
- GOVX $3,353,560.00
- NERV N/A
- Revenue This Year
- GOVX N/A
- NERV N/A
- Revenue Next Year
- GOVX N/A
- NERV N/A
- P/E Ratio
- GOVX N/A
- NERV N/A
- Revenue Growth
- GOVX 8.52
- NERV N/A
- 52 Week Low
- GOVX $0.37
- NERV $1.15
- 52 Week High
- GOVX $3.01
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- GOVX 35.66
- NERV 49.13
- Support Level
- GOVX $0.37
- NERV $3.76
- Resistance Level
- GOVX $0.44
- NERV $4.42
- Average True Range (ATR)
- GOVX 0.03
- NERV 0.32
- MACD
- GOVX -0.00
- NERV -0.09
- Stochastic Oscillator
- GOVX 26.59
- NERV 25.93
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.